- ANI Pharmaceuticals (NASDAQ:ANIP +5.4%) acquires Noven Therapeutics' NDA for Lithobid (lithium carbonate extended release 300 mg tablets) for an $11M upfront payment plus a $1M future milestone payment. ANI intends to launch the product under its own label in July. Previously, ANI contract manufactured the product for Noven.
ANI acquires lithium drug from Noven
Recommended For You
More Trending News
About ANIP Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ANIP | - | - |
ANI Pharmaceuticals, Inc. |